 BeyondSpring the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office USPTO has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia CIN from Taxane in cancer patients by administering its lead asset Plinabulin, with protection through 2033. This is the first U.S. patent establishing Plinabulins beneficial effects in reducing CIN associated with taxane, one of the most commonly used chemotherapies, said Dr. Lan Huang, BeyondSprings Co-founder, Chairman and CEO, and the inventor of this patent. 